Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guardian Pharmacy ServicesGRDN +0.37%42 Return-on-Tangible-Asset is 16.51% as of Mar. 2026, which is 19% above its 10-year median of 13.89. GuruFocus rates GRDN with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Guardian Pharmacy Services ranks better than 94% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Guardian Pharmacy Services's annualizedNet Income for the quarter that ended in Mar. 2026 was $53 Mil. Guardian Pharmacy Services's average total tangible assets for the quarter that ended in Mar. 2026 was $322 Mil. Therefore, Guardian Pharmacy Services's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 16.51%.
The historical rank and industry rank for Guardian Pharmacy Services's Return-on-Tangible-Asset or its related term are showing as below:
GRDN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -39.7 Med: 13.89 Max: 20.25
Current: 18.31
During the past 8 years, Guardian Pharmacy Services's highest Return-on-Tangible-Asset was 20.25%. The lowest was -39.70%. And the median was 13.89%.
GRDN's Return-on-Tangible-Asset is ranked better than 94% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 2.43
vs GRDN: 18.31
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Guardian Pharmacy Services Return-on-Tangible-Asset Related Terms
Guardian Pharmacy Services Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRDN vs ACHC, ASTH, NHC: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, Guardian Pharmacy Services's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardian Pharmacy Services Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Guardian Pharmacy Services's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Guardian Pharmacy Services's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 16.51% mean?
Guardian Pharmacy Services (GRDN) has a Return-on-Tangible-Asset of 16.51% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Guardian Pharmacy Services and its competitors. This is 19% above median its historical median of 13.89. According to the industry distribution chart, Guardian Pharmacy Services ranks #41 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 6%.
Is Guardian Pharmacy Services' Return-on-Tangible-Asset too high?
Guardian Pharmacy Services' current Return-on-Tangible-Asset of 16.51% is 19% above median its 10-year median of 13.89. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.43. Guardian Pharmacy Services' value of 16.51% is 579.4% above this industry median. Based on the distribution chart, Guardian Pharmacy Services ranks #41 out of 683 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Guardian Pharmacy Services has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Guardian Pharmacy Services' Return-on-Tangible-Asset compare to ACHC and ASTH?
According to the Healthcare Providers & Services industry distribution chart, Guardian Pharmacy Services ranks #41 out of 683 companies for Return-on-Tangible-Asset. This places Guardian Pharmacy Services in the top 6% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.43. Guardian Pharmacy Services' value of 16.51% is 579.4% above this benchmark. While the company's 10-year median is 13.89 vs. the industry median of 2.43, Guardian Pharmacy Services has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.43, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guardian Pharmacy Services's current Return-on-Tangible-Asset of 16.51% is 579.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Guardian Pharmacy Services and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guardian Pharmacy Services's current Return-on-Tangible-Asset is 16.51%, which is 19% above median its own 10-year median of 13.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardian Pharmacy Services stock overvalued right now?
Guardian Pharmacy Services (GRDN) has a current Return-on-Tangible-Asset of 16.51%. The current Return-on-Tangible-Asset is 16.51%, which is 19% above median its 10-year median of 13.89 and 579.4% above the Healthcare Providers & Services industry median of 2.43. Guardian Pharmacy Services' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Guardian Pharmacy Services (GRDN), the current Return-on-Tangible-Asset is 16.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.
42GF Score
Get the complete analysis for GRDN
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRDN has been successfully added to your 
